The disclosure relates to isolated microorganismsincluding novel strains of the microorganismsmicrobial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methy19243-yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.

The present invention relates to the use of misoprostol for the induction of labour in a pregnant female, and in particular to the use of a sustained delivery device or insert containing substantially 200 g misoprostol for intravaginal use. The use encompasses methods of therapy as well as compositions for use in such methods.

The present invention relates to pharmaceutical compositions having improved stability.

The present invention relates to pharmaceutical compositions having improved stability.

Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X.sup.1, X.sup.2, X.sup.3, X.sup.4, and X.sup.5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X.sup.1, X.sup.2, X.sup.3, X.sup.4, and X.sup.5 are maintained; one or two R.sup.6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R.sup.6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R.sup.6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an -, -, or -position to the carbon atom to which the R.sup.6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

##STR00001##

The present invention provides a compound of formula I; ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same. ##STR00001##

The present invention relates to pharmaceutical compositions having improved stability.